Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Intangibles (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Intangibles data on record, last reported at $1.6 million in Q2 2025.

  • For Q2 2025, Intangibles fell 9.12% year-over-year to $1.6 million; the TTM value through Jun 2025 reached $1.6 million, down 9.12%, while the annual FY2025 figure was $1.6 million, 9.12% down from the prior year.
  • Intangibles reached $1.6 million in Q2 2025 per INM's latest filing, down from $1.8 million in the prior quarter.
  • Across five years, Intangibles topped out at $2.9 million in Q1 2024 and bottomed at $300000.0 in Q2 2023.
  • Average Intangibles over 5 years is $1.6 million, with a median of $1.7 million recorded in 2021.
  • Peak YoY movement for Intangibles: crashed 82.72% in 2023, then surged 494.4% in 2024.
  • A 5-year view of Intangibles shows it stood at $1.7 million in 2021, then changed by 0.0% to $1.7 million in 2022, then grew by 9.72% to $1.9 million in 2023, then decreased by 6.41% to $1.8 million in 2024, then decreased by 9.12% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Intangibles were $1.6 million in Q2 2025, $1.8 million in Q2 2024, and $2.9 million in Q1 2024.